Other Information
−Removed: During the three months ended March 31, 2026, the following director adopted a Rule 10b5-1 trading arrangement (as such terms are defined pursuant to Item 408 of Regulation S-K) as noted in the table below.
+Added: During the three months ended June 30, 2026, the following director adopted Rule 10b5-1 trading arrangements (as such terms are defined pursuant to Item 408 of Regulation S-K) as noted in the table below.
Trading Arrangement
3 unchanged sentences
Expiration Date
−Removed: Mahesh Krishnan
−Removed: 7,304 6/1/2027
+Added: Matthew Posard Adoption 6/15/2026 X 49,102 3/31/2027
* Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
11 unchanged sentences
and The Bank of New York Mellon Trust Company, N.A., as trustee (included within Exhibit 4.3) ( filed as Exhibit 4.2 to the Company’s Form 8-K filed August 18, 2022 and incorporated herein by reference )
−Removed: 4.5 2031 Convertible Notes I ndenture, dated November 12, 2025, between Halozyme Ther apeutics, Inc.
−Removed: and The Bank of New York Mellon Trust Company , N.A., as tr ustee (filed as Exhibit 4.1 to the Company ’ s Form 8-K filed November 12, 2025 and incorporated herein by reference)
−Removed: 4.6 F orm of 0% Convertible Senior Notes due 2031 (included with in Exhibit 4.5) (filed as Exhibit 4.2 to the C ompany ’ s Form 8-K filed November 12, 2025 and incorporated herein by ref erence)
4.5 2031 Convertible Notes Indenture, dated November 12, 2025, between Halozyme Therapeutics, Inc.
−Removed: and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.
−Removed: 3 to the Company’s Form 8-K filed November 12, 2025 and incorporated herein by reference)
−Removed: 4.8 Form of 0 .875 % Convertible Senior Notes due 203 2 (included within Exhibit 4.
−Removed: 7 ) (filed as Exhibit 4.
−Removed: 4 to the Company’s Form 8-K filed November 12, 2025 and incorporated herein by reference)
+Added: and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.1 to the Company’s Form 8-K filed November 12, 2025 and incorporated herein by reference)
+Added: 4.6 Form of 0% Convertible Senior Notes due 2031 (included within Exhibit 4.5) (filed as Exhibit 4.2 to the Company’s Form 8-K filed November 12, 2025 and incorporated herein by reference)
+Added: 4.7 2032 Convertible Notes Indenture, dated November 12, 2025, between Halozyme Therapeutics, Inc.
+Added: and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.3 to the Company’s Form 8-K filed November 12, 2025 and incorporated herein by reference)
+Added: 4.8 Form of 0.875% Convertible Senior Notes due 2032 (included within Exhibit 4.7) (filed as Exhibit 4.4 to the Company’s Form 8-K filed November 12, 2025 and incorporated herein by reference)
31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended (filed herewith)
11 unchanged sentences
Halozyme Therapeutics, Inc.
−Removed: May 11, 2026 By:
+Added: August 6, 2026 By:
Ch.B., M.R.C.P.
2 unchanged sentences
(Principal Executive Officer)
−Removed: May 11, 2026 By:
−Removed: /s/ David Ramsay
−Removed: Interim Chief Financial Officer
+Added: August 6, 2026 By:
+Added: /s/ Darren Snellgrove
+Added: Darren Snellgrove
+Added: Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.